Researchers at the Technical University of Denmark have utilized AI to design a novel protein, termed minibinder, that enhances T cell interactions with cancer antigens, significantly reducing the time required for development from over a year to several weeks. Their study shows that these minibinders can effectively target cancer cells, including those expressing NY-ESO-1, and hold potential for future applications in both cancer therapy and autoimmune diseases.